These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

589 related items for PubMed ID: 22024510

  • 1. Valganciclovir as pre-emptive therapy for cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients.
    Ruiz-Camps I, Len O, de la Cámara R, Gurguí M, Martino R, Jarque I, Barrenetxea C, Díaz de Heredia C, Batlle M, Rovira M, de la Torre J, Torres A, Aguilar M, Espigado I, Martín-Dávila P, Bou G, Borrell N, Aguado JM, Pahissa A, Spanish Network for Research on Infection in Transplantation (RESITRA/REIPI). Spain.
    Antivir Ther; 2011; 16(7):951-7. PubMed ID: 22024510
    [Abstract] [Full Text] [Related]

  • 2. Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients.
    Len O, Gavaldà J, Aguado JM, Borrell N, Cervera C, Cisneros JM, Cuervas-Mons V, Gurguí M, Martin-Dávila P, Montejo M, Muñoz P, Bou G, Carratalà J, Torre-Cisneros J, Pahissa A, RESITRA.
    Clin Infect Dis; 2008 Jan 01; 46(1):20-7. PubMed ID: 18171208
    [Abstract] [Full Text] [Related]

  • 3. Occurrence of adverse events caused by valganciclovir as pre-emptive therapy for cytomegalovirus infection after allogeneic stem cell transplantation is reduced by low-dose administration.
    Takahata M, Hashino S, Nishio M, Sugita J, Shigematsu A, Onozawa M, Fujimoto K, Endo T, Kondo T, Tanaka J, Imamura M, Teshima T.
    Transpl Infect Dis; 2015 Dec 01; 17(6):810-5. PubMed ID: 26354293
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients.
    van der Heiden PL, Kalpoe JS, Barge RM, Willemze R, Kroes AC, Schippers EF.
    Bone Marrow Transplant; 2006 Apr 01; 37(7):693-8. PubMed ID: 16501590
    [Abstract] [Full Text] [Related]

  • 10. High efficacy and low toxicity of short-course oral valganciclovir as pre-emptive therapy for hematopoietic stem cell transplant cytomegalovirus infection.
    Saleh AJ, Al Mohareb F, Al Rabiah F, Chaudhri N, Al Sharif F, Al Zahrani H, Mohamed SY, Patel M, Rasheed W, Nurgat Z, Bakr M, Ahmed S, Zaidi S, Nasser A, Ibrahim K, Al Abdely H, Aljurf M.
    Hematol Oncol Stem Cell Ther; 2010 Apr 01; 3(3):116-20. PubMed ID: 20890068
    [Abstract] [Full Text] [Related]

  • 11. Cytomegalovirus Infection in Pediatric Renal Transplantation and the Impact of Chemoprophylaxis With (Val-)Ganciclovir.
    Höcker B, Zencke S, Krupka K, Fichtner A, Pape L, Dello Strologo L, Guzzo I, Topaloglu R, Kranz B, König J, Bald M, Webb NJ, Noyan A, Dursun H, Marks S, Yalcinkaya F, Thiel F, Billing H, Pohl M, Fehrenbach H, Bruckner T, Tönshoff B.
    Transplantation; 2016 Apr 01; 100(4):862-70. PubMed ID: 26736017
    [Abstract] [Full Text] [Related]

  • 12. Half-dose ganciclovir preemptive treatment of cytomegalovirus infection after pediatric allogeneic hematopoietic stem cell transplantation.
    Ju HY, Kang HJ, Hong CR, Lee JW, Kim H, Park KD, Shin HY, Park JD, Choi EH, Lee HJ, Ahn HS.
    Transpl Infect Dis; 2016 Jun 01; 18(3):396-404. PubMed ID: 27041364
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients.
    Park JM, Lake KD, Arenas JD, Fontana RJ.
    Liver Transpl; 2006 Jan 01; 12(1):112-6. PubMed ID: 16382458
    [Abstract] [Full Text] [Related]

  • 15. Sequential treatment of cytomegalovirus infection or disease with a short course of intravenous ganciclovir followed by oral valganciclovir: efficacy, safety, and pharmacokinetics.
    Caldés A, Gil-Vernet S, Armendariz Y, Colom H, Pou L, Niubó J, Lladó L, Torras J, Manito N, Rufí G, Grinyó JM.
    Transpl Infect Dis; 2010 Jun 01; 12(3):204-12. PubMed ID: 20002612
    [Abstract] [Full Text] [Related]

  • 16. Valganciclovir as pre-emptive therapy for cytomegalovirus infection post-allogenic stem cell transplantation: implications for the emergence of drug-resistant cytomegalovirus.
    Allice T, Busca A, Locatelli F, Falda M, Pittaluga F, Ghisetti V.
    J Antimicrob Chemother; 2009 Mar 01; 63(3):600-8. PubMed ID: 19147520
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Valganciclovir for pre-emptive therapy of cytomegalovirus viraemia after hematopoietic stem cell transplantation: a prospective multi-center trial.
    Liu KY, Wang Y, Han MZ, Huang H, Chen H, Liu QF, Wang JM, Liu T, Song YP, Ma J, Wu DP, Zou P, Huang XJ.
    Chin Med J (Engl); 2010 Aug 01; 123(16):2199-205. PubMed ID: 20819665
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Low-dose valgancyclovir as cytomegalovirus reactivation prophylaxis in allogeneic haematopoietic stem cell transplantation.
    Serio B, Rosamilio R, Giudice V, Pepe S, Zeppa P, Esposiito S, Pezzullo L, Rocco M, Montuori N, Selleri C.
    Infez Med; 2012 Aug 01; 20 Suppl 2():26-34. PubMed ID: 23042003
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.